Rasha Haggag
Research Subjects
Research Interests
Rasha Haggag has a total of 59 co-authors. Here are the top co-authors by number of shared publications:
- Abdel-Rahman Nabawy Zekri
Virology and Immunology Unit, Cancer Biology Department, National Cancer Institute, Cairo University, Cairo 11976, Egypt
3 shared publications Fouad Abu-Taleb
Medical Oncology Department, Faculty of Medicine, Zagazig University, Zagazig 44519, Egypt
3 shared publications- Fouad Abu-Taleb
Department of Medical Oncology, Faculty of Medicine, Zagazig University, Egypt
2 shared publications - Hussein Khaled
Medical Oncology Department, National Cancer Institute, Cairo University, Cairo 11796, Egypt
2 shared publications - Samy Ahmed Alsirafy
Palliative Medicine Unit, Kasr Al-Ainy Center of Clinical Oncology and Nuclear Medicine, Kasr Al-Ainy School of Medicine, Cairo University, Cairo, Egypt
2 shared publications Shereen El Shorbagy
Medical Oncology Department, Faculty of Medicine, Zagazig University, Zagazig, 44519, Egypt
2 shared publications
Latest Publications
- Open Access
- 1 July 2021
- Published by Egyptian Knowledge Bank in The Egyptian Journal of Hospital Medicine
- Vol. 84 (1) , 2400-2404
Diagnosis of Sepsis among Adult Patients with AML Using Scd14
Background: Millions of dead cases are reported every year due to sepsis. Sepsis has been estimated in 1-2 % of hospitalized patients especially leukemic patients. The diagnosis of sepsis remains a clinical challenge. Many studies suggest that presepsin plays a role in diagnosing sepsis, but the results remain controversial. Objective: To evaluate the potential of presepsin as an early biochemical marker of sepsis in adult acute leukemic patients and to assess the correlation between severity of sepsis and level of presepsin. Comparing between presepsin & CRP in diagnosing bacterial infection in critically ill adult leukemic patients. Patients and Methods: This study was conducted on 24 patients having acute leukemia after receiving chemotherapy and 24 controls at Medical Oncology and Clinical Pathology Departments, Zagazig University Hospitals during the period from June 2018 to August 2019. Results: There was statistically significant difference between patients and control regarding presepsin levels. The highest levels of presepsin were in patients with septic shock followed by severe sepsis, sepsis, SIRS then control group. There was statistically significant difference between types of sepsis and presepsin (P value = 0.000). There was statistically significant positive correlation between CRP and presepsin (r = 0.658). AT cut off value of 440 the clinical sensitivity of presepsin was 82.5% and its clinical specificity was 90%, AUC was 0.89. On comparing these results with the normal cut off value of CRP level (6), the clinical sensitivity and specificity were 90% & 61% respectively and AUC was 0.70. Conclusion: Presepsin can be used as a better indicator to the degree of severity of sepsis than CRP in septic adult leukemic patients.
- 1 July 2021
- Published by Egyptian Knowledge Bank in The Egyptian Journal of Hospital Medicine
- Vol. 84 (1) , 2400-2404
Open AccessDiagnosis of Sepsis among Adult Patients with AML Using Scd14
Background: Millions of dead cases are reported every year due to sepsis. Sepsis has been estimated in 1-2 % of hospitalized patients especially leukemic patients. The diagnosis of sepsis remains a clinical challenge. Many studies suggest that presepsin plays a role in diagnosing sepsis, but the results remain controversial. Objective: To evaluate the potential of presepsin as an early biochemical marker of sepsis in adult acute leukemic patients and to assess the correlation between severity of sepsis and level of presepsin. Comparing between presepsin & CRP in diagnosing bacterial infection in critically ill adult leukemic patients. Patients and Methods: This study was conducted on 24 patients having acute leukemia after receiving chemotherapy and 24 controls at Medical Oncology and Clinical Pathology Departments, Zagazig University Hospitals during the period from June 2018 to August 2019. Results: There was statistically significant difference between patients and control regarding presepsin levels. The highest levels of presepsin were in patients with septic shock followed by severe sepsis, sepsis, SIRS then control group. There was statistically significant difference between types of sepsis and presepsin (P value = 0.000). There was statistically significant positive correlation between CRP and presepsin (r = 0.658). AT cut off value of 440 the clinical sensitivity of presepsin was 82.5% and its clinical specificity was 90%, AUC was 0.89. On comparing these results with the normal cut off value of CRP level (6), the clinical sensitivity and specificity were 90% & 61% respectively and AUC was 0.70. Conclusion: Presepsin can be used as a better indicator to the degree of severity of sepsis than CRP in septic adult leukemic patients.
- 24 March 2020
- Published by Springer Nature in Journal of Gastrointestinal Cancer
- Vol. 52 (1) , 269-279
Prognostic Significance of VEGF and HIF-1 α in Hepatocellular Carcinoma Patients Receiving Sorafenib Versus Metformin Sorafenib Combination
Background Hepatocellular carcinoma (HCC) is a major health problem. HCC burden has been increasing in Egypt in the past 10 years. Most HCC cases are diagnosed at an advanced stage with limited treatment options. Sorafenib is the standard therapy for advanced HCC, but the effectiveness is not satisfied. Metformin may decrease the risk of HCC development in diabetic patients, reduces tumor invasion, and augments sensitivity to sorafenib; however, safety and efficacy of combined treatment are still unclear. As HCC is characterized by high vascularity, and vascular endothelial growth factor (VEGF) plays an important role in vascularization, many studies questioned if VEGF and HIF-1 α could offer information about HCC response to sorafenib. We conducted this study to assess the benefits from adding metformin to HCC treatment, and appraise the role of VEGF and HIF-1 α in HCC prognosis. Method This was a prospective, randomized study in which 80 advanced measurable patients consecutively treated with sorafenib plus metformin (arm A) or sorafenib alone (arm B), prognostic value of plasma, and tissue levels of VEGF and HIF-1 α were evaluated. Results We enrolled 61 men and 19 women with a median age of 60 years (range 49–68 years). Fifty-seven patients had Child–Pugh A while 23 had early B, the most common etiology of liver disease was hepatitis C (86%). Sixty percent of patients were diabetic. No significant difference was detected between arm A and arm B regarding response to treatment (p = 0.5), time to disease progression (p = 0.3), or overall survival (p = 0.6). Low VEGF and HIF-1 α plasma levels were significantly associated with better treatment response (p < 0.001 for both), and higher OS (p < 0.001). Patients with high expressions of VEGF and HIF in HCC tissue had significantly poor treatment outcome (p < 0.001, p = 0.03, respectively), and poor OS (p < 0.001, p < 0.001, respectively). Conclusions No superior efficacy of adding metformin to sorafenib in HCC treatment. VEGF and HIF-1 α had promising prognostic value in HCC.
- 24 March 2020
- Published by Springer Nature in Journal of Gastrointestinal Cancer
- Vol. 52 (1) , 269-279
Prognostic Significance of VEGF and HIF-1 α in Hepatocellular Carcinoma Patients Receiving Sorafenib Versus Metformin Sorafenib Combination
Background Hepatocellular carcinoma (HCC) is a major health problem. HCC burden has been increasing in Egypt in the past 10 years. Most HCC cases are diagnosed at an advanced stage with limited treatment options. Sorafenib is the standard therapy for advanced HCC, but the effectiveness is not satisfied. Metformin may decrease the risk of HCC development in diabetic patients, reduces tumor invasion, and augments sensitivity to sorafenib; however, safety and efficacy of combined treatment are still unclear. As HCC is characterized by high vascularity, and vascular endothelial growth factor (VEGF) plays an important role in vascularization, many studies questioned if VEGF and HIF-1 α could offer information about HCC response to sorafenib. We conducted this study to assess the benefits from adding metformin to HCC treatment, and appraise the role of VEGF and HIF-1 α in HCC prognosis. Method This was a prospective, randomized study in which 80 advanced measurable patients consecutively treated with sorafenib plus metformin (arm A) or sorafenib alone (arm B), prognostic value of plasma, and tissue levels of VEGF and HIF-1 α were evaluated. Results We enrolled 61 men and 19 women with a median age of 60 years (range 49–68 years). Fifty-seven patients had Child–Pugh A while 23 had early B, the most common etiology of liver disease was hepatitis C (86%). Sixty percent of patients were diabetic. No significant difference was detected between arm A and arm B regarding response to treatment (p = 0.5), time to disease progression (p = 0.3), or overall survival (p = 0.6). Low VEGF and HIF-1 α plasma levels were significantly associated with better treatment response (p < 0.001 for both), and higher OS (p < 0.001). Patients with high expressions of VEGF and HIF in HCC tissue had significantly poor treatment outcome (p < 0.001, p = 0.03, respectively), and poor OS (p < 0.001, p < 0.001, respectively). Conclusions No superior efficacy of adding metformin to sorafenib in HCC treatment. VEGF and HIF-1 α had promising prognostic value in HCC.
- Open Access
- 1 March 2017
- Published by Elsevier in Journal of Advanced Research
- Vol. 8 (2) , 131-137
Hepatitis C virus and non-Hodgkin’s lymphomas: A minireview
- 1 March 2017
- Published by Elsevier in Journal of Advanced Research
- Vol. 8 (2) , 131-137
Open AccessHepatitis C virus and non-Hodgkin’s lymphomas: A minireview
- Open Access
- 17 January 2017
- Published by Wiley in Journal of Oncology
- Vol. 2017, 1-9
The Prognostic Role of NEDD9 and P38 Protein Expression Levels in Urinary Bladder Transitional Cell Carcinoma
Background. The most common malignant tumor of the urinary bladder is transitional cell carcinoma (TCC). Neural precursor cell-expressed developmentally downregulated protein 9 (NEDD9) is found to be a cell adhesion mediator. P38 Mitogen-Activated Protein Kinase is a serine/threonine kinases member which can mediate carcinogenesis through intracellular signaling. Methods. To assess their prognostic role; NEDD9 and p38 protein were evaluated in sections from 50 paraffin blocks of TCC. Results. The high expressions of NEDD9 and p38 protein were significantly associated with grade, stage, distant metastasis (), number of tumors, lymph node metastasis, and tumor size (, 0.002; 0.018, <0.001; and 0.004, 0.007, respectively). High NEDD9 and p38 detection had a worse 3-year OS ( and <0.001, respectively). By multivariate analysis the NEDD9 and p38 protein expression levels and various clinicopathological criteria including gender, grade, stage of the tumor, and regional lymph node involvement were independent prognostic parameters of TCC of the urinary bladder patients’ outcome. Conclusion. NEDD9 and p38 protein expressions were poor prognostic markers of TCC.- 17 January 2017
- Published by Wiley in Journal of Oncology
- Vol. 2017, 1-9
Open AccessThe Prognostic Role of NEDD9 and P38 Protein Expression Levels in Urinary Bladder Transitional Cell Carcinoma
Background. The most common malignant tumor of the urinary bladder is transitional cell carcinoma (TCC). Neural precursor cell-expressed developmentally downregulated protein 9 (NEDD9) is found to be a cell adhesion mediator. P38 Mitogen-Activated Protein Kinase is a serine/threonine kinases member which can mediate carcinogenesis through intracellular signaling. Methods. To assess their prognostic role; NEDD9 and p38 protein were evaluated in sections from 50 paraffin blocks of TCC. Results. The high expressions of NEDD9 and p38 protein were significantly associated with grade, stage, distant metastasis (), number of tumors, lymph node metastasis, and tumor size (, 0.002; 0.018, <0.001; and 0.004, 0.007, respectively). High NEDD9 and p38 detection had a worse 3-year OS ( and <0.001, respectively). By multivariate analysis the NEDD9 and p38 protein expression levels and various clinicopathological criteria including gender, grade, stage of the tumor, and regional lymph node involvement were independent prognostic parameters of TCC of the urinary bladder patients’ outcome. Conclusion. NEDD9 and p38 protein expressions were poor prognostic markers of TCC. - Open Access
- 31 December 2016
- Published by International Journal Of Advanced Research in International Journal of Advanced Research
- Vol. 4 (12) , 1102-1114
CLINICOPATHOLOGICAL SIGNIFICANCE OF CANCER STEM CELLS (CD 44 AND CD133) AND INFLAMMATORY MICROENVIRONMENT (TAMS AND MAST CELLS) IN COLORECTAL CANCER: IMMUNOHISTOCHEMICAL STUDY.
- 31 December 2016
- Published by International Journal Of Advanced Research in International Journal of Advanced Research
- Vol. 4 (12) , 1102-1114
Open AccessCLINICOPATHOLOGICAL SIGNIFICANCE OF CANCER STEM CELLS (CD 44 AND CD133) AND INFLAMMATORY MICROENVIRONMENT (TAMS AND MAST CELLS) IN COLORECTAL CANCER: IMMUNOHISTOCHEMICAL STUDY.
- Open Access
- 1 December 2016
- Published by Egyptian Knowledge Bank in Research in Oncology
- Vol. 12 (2) , 60-63
Awareness of Diagnosis in Patients with Cancer: A Study from Egypt
Background: One of the barriers to cancer care is the inadequate communication with patients and their families. InEgypt, it is believed that culture is against the honest disclosure of cancer diagnosis. So, the majority of cancer patientsare usually unaware of their diagnosis.Aim: To study cancer diagnosis awareness among a group of Egyptian patients and the factors contributing to their unawareness. Methods: The study included 119 cancer patients from two cancer centers; one in Cairo and the other in Sharkia. Patients were asked about their illness and who answered as having cancer/tumor” or mentioned the name of cancer considered aware. Results: The majority of our patients (100/119, 84%) were aware of their cancer diagnosis. Their answer was “cancer” in 31%, “tumor” in 60% and the name of cancer in 9%. While, a nority (19 /119, 16%), were unaware of their cancer diagnosis. They were more likely to be less educated, older in age, males, unmarried, and from Sharkia. None of the studied variables associated significantly with awareness. Conclusions: The results of this study suggest that most cancer patients in Egypt are aware of their diagnosis. This may be due to a change in the Egyptian cultural attitude towards truth telling and a shift in the approach of care from paternalistic to patient-centred.
- 1 December 2016
- Published by Egyptian Knowledge Bank in Research in Oncology
- Vol. 12 (2) , 60-63
Open AccessAwareness of Diagnosis in Patients with Cancer: A Study from Egypt
Background: One of the barriers to cancer care is the inadequate communication with patients and their families. InEgypt, it is believed that culture is against the honest disclosure of cancer diagnosis. So, the majority of cancer patientsare usually unaware of their diagnosis.Aim: To study cancer diagnosis awareness among a group of Egyptian patients and the factors contributing to their unawareness. Methods: The study included 119 cancer patients from two cancer centers; one in Cairo and the other in Sharkia. Patients were asked about their illness and who answered as having cancer/tumor” or mentioned the name of cancer considered aware. Results: The majority of our patients (100/119, 84%) were aware of their cancer diagnosis. Their answer was “cancer” in 31%, “tumor” in 60% and the name of cancer in 9%. While, a nority (19 /119, 16%), were unaware of their cancer diagnosis. They were more likely to be less educated, older in age, males, unmarried, and from Sharkia. None of the studied variables associated significantly with awareness. Conclusions: The results of this study suggest that most cancer patients in Egypt are aware of their diagnosis. This may be due to a change in the Egyptian cultural attitude towards truth telling and a shift in the approach of care from paternalistic to patient-centred.
- Open Access
- 24 August 2016
- Published by Springer Nature in Egyptian Journal of Radiology and Nuclear Medicine
- Vol. 47 (4) , 1349-1359
Ultrasound elastography in pathological enlarged cervical lymph nodes compared to histopathology
- 24 August 2016
- Published by Springer Nature in Egyptian Journal of Radiology and Nuclear Medicine
- Vol. 47 (4) , 1349-1359
Open AccessUltrasound elastography in pathological enlarged cervical lymph nodes compared to histopathology
- 20 May 2016
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34 (15_suppl) , e19039
Rituximab-induced hepatitis C virus reactivation in HCV-positive patients with diffuse large B-cell lymphoma.
E19039 Background: The clinical outcome and hepatic toxicity occurrence of diffuse large B-cell lymphoma (DLBCL) patients with hepatitis C virus (HCV) infection in the rituximab era remains controversial. Methods: To elucidate the characteristics of DLBCL patients in relation to HCV infection status, we retrospectively analyzed DLBCL patients diagnosed and treated with chemo- or immunochemotherapy at our institutes and at a private hospital during the last decade. Of the 132 patients, 64(48.5%) and 68 (51.5%) patients received RCHOP and CHOP, respectively. Results::In all, HCV infection was identified in 35(26.5%) of 132 DLBCL patients. Except for being more likely to present with B symptoms and splenic involvement, patients with HCV infection were demographically indistinguishable from HCV-negative patients. Multivariate analysis of the whole group showed 3 factors found to independently predict an inferior OS including extra-nodal involvement ( ≤ 1 vs. > 1; HR = 4.5, 95% CI = 1.6-12.6, p = 0.012 ) , splenic involvement( presence vs. absence; HR = 0.5, 95% CI = 0.33-0.82 , p = 0.0008) , and performance status (0-1 vs. > 1; HR = 2.9, 95% CI = 1.6-12.6 ,p = 0.04). Adverse effects on DFS was significant only with splenic involvement (presence vs. absence; HR = 0.6, 95% CI = 0.45-0.9, p = 0.04). Among the HCV-infected patients, the incidence of hepatitis flares was 40%; (14/35)patients vs. 9.3% (9/97) patientsamong the HCV-uninfected individuals (P = < 0.001). Of the 35 HCV-positive patients,14 (40%) received R-CHOPand 21 (60%) received CHOP.HCV reactivation occurred in 34.2% (11/35 patients) without any relation to treatment regimen (7 (11%) for RCHOP and 5(7.3%) for CHOP;p = 0.3). No hepatic toxicity related deathshad been reported. Conclusions: our study results demonstrated that HCV infection did not influence the clinical outcome of DLBCL patients, and its reactivation has no relation to the type of treatment.
- 20 May 2016
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34 (15_suppl) , e19039
Rituximab-induced hepatitis C virus reactivation in HCV-positive patients with diffuse large B-cell lymphoma.
E19039 Background: The clinical outcome and hepatic toxicity occurrence of diffuse large B-cell lymphoma (DLBCL) patients with hepatitis C virus (HCV) infection in the rituximab era remains controversial. Methods: To elucidate the characteristics of DLBCL patients in relation to HCV infection status, we retrospectively analyzed DLBCL patients diagnosed and treated with chemo- or immunochemotherapy at our institutes and at a private hospital during the last decade. Of the 132 patients, 64(48.5%) and 68 (51.5%) patients received RCHOP and CHOP, respectively. Results::In all, HCV infection was identified in 35(26.5%) of 132 DLBCL patients. Except for being more likely to present with B symptoms and splenic involvement, patients with HCV infection were demographically indistinguishable from HCV-negative patients. Multivariate analysis of the whole group showed 3 factors found to independently predict an inferior OS including extra-nodal involvement ( ≤ 1 vs. > 1; HR = 4.5, 95% CI = 1.6-12.6, p = 0.012 ) , splenic involvement( presence vs. absence; HR = 0.5, 95% CI = 0.33-0.82 , p = 0.0008) , and performance status (0-1 vs. > 1; HR = 2.9, 95% CI = 1.6-12.6 ,p = 0.04). Adverse effects on DFS was significant only with splenic involvement (presence vs. absence; HR = 0.6, 95% CI = 0.45-0.9, p = 0.04). Among the HCV-infected patients, the incidence of hepatitis flares was 40%; (14/35)patients vs. 9.3% (9/97) patientsamong the HCV-uninfected individuals (P = < 0.001). Of the 35 HCV-positive patients,14 (40%) received R-CHOPand 21 (60%) received CHOP.HCV reactivation occurred in 34.2% (11/35 patients) without any relation to treatment regimen (7 (11%) for RCHOP and 5(7.3%) for CHOP;p = 0.3). No hepatic toxicity related deathshad been reported. Conclusions: our study results demonstrated that HCV infection did not influence the clinical outcome of DLBCL patients, and its reactivation has no relation to the type of treatment.
- Open Access
- 1 January 2016
- Published by ScopeMed in Journal of Interdisciplinary Histopathology
- Vol. 4 (1) , 1
Prognostic Implication of MYSM-1 and Twist-1 in Renal Cell Carcinoma
Objective: The data available regarding the epithelial-mesenchymal transition (EMT) markers are little. This study aimed to evaluate the immunohistochemical expression of EMT markers; MYb-like, Swirm and Mpn domain-containing protein-1 (MYSM-1) and Twist-1 in renal cell carcinoma (RCC), in a trial to find their role in the prognosis of such type of cancer. Methods: Immunoexpressions of MYb-like, Swirm and Mpn domain-containing protein-1 (MYSM-1) and Twist-1 were assessed in tissue specimens of 50 patients with RCC, and correlated with other clinicopathological features. The findings and their correlations were statistically determined. Results: Low expression of MYSM-1 was negatively correlated with size of the tumor, primary tumor (pT) stage, Fuhrman grade (P Key words: Renal cell carcinoma, Immunohistochemical expression, MYSM-1, Twist-1, Prognosis
- 1 January 2016
- Published by ScopeMed in Journal of Interdisciplinary Histopathology
- Vol. 4 (1) , 1
Open AccessPrognostic Implication of MYSM-1 and Twist-1 in Renal Cell Carcinoma
Objective: The data available regarding the epithelial-mesenchymal transition (EMT) markers are little. This study aimed to evaluate the immunohistochemical expression of EMT markers; MYb-like, Swirm and Mpn domain-containing protein-1 (MYSM-1) and Twist-1 in renal cell carcinoma (RCC), in a trial to find their role in the prognosis of such type of cancer. Methods: Immunoexpressions of MYb-like, Swirm and Mpn domain-containing protein-1 (MYSM-1) and Twist-1 were assessed in tissue specimens of 50 patients with RCC, and correlated with other clinicopathological features. The findings and their correlations were statistically determined. Results: Low expression of MYSM-1 was negatively correlated with size of the tumor, primary tumor (pT) stage, Fuhrman grade (P Key words: Renal cell carcinoma, Immunohistochemical expression, MYSM-1, Twist-1, Prognosis
- Open Access
- 29 April 2015
- Published by Asian Pacific Organization for Cancer Prevention in Asian Pacific Journal of Cancer Prevention
- Vol. 16 (8) , 3543-3549
Differentially Expressed Genes in Metastatic Advanced Egyptian Bladder Cancer
Background: Bladder cancer is one of the most common cancers worldwide. Gene expression profiling using microarray technologies improves the understanding of cancer biology. The aim of this study was to determine the gene expression profile in Egyptian bladder cancer patients. Materials and Methods: Samples from 29 human bladder cancers and adjacent non-neoplastic tissues were analyzed by cDNA microarray, with hierarchical clustering and multidimensional analysis. Results: Five hundred and sixteen genes were differentially expressed of which SOS1, HDAC2, PLXNC1, GTSE1, ULK2, IRS2, ABCA12, TOP3A, HES1, and SRP68 genes were involved in 33 different pathways. The most frequently detected genes were: SOS1 in 20 different pathways; HDAC2 in 5 different pathways; IRS2 in 3 different pathways. There were 388 down-regulated genes. PLCB2 was involved in 11 different pathways, MDM2 in 9 pathways, FZD4 in 5 pathways, p15 and FGF12 in 4 pathways, POLE2 in 3 pathways, and MCM4 and POLR2E in 2 pathways. Thirty genes showed significant differences between transitional cell cancer (TCC) and squamous cell cancer (SCC) samples. Unsupervised cluster analysis of DNA microarray data revealed a clear distinction between low and high grade tumors. In addition 26 genes showed significant differences between low and high tumor stages, including fragile histidine triad, Ras and sialyltransferase 8 (alpha) and 16 showed significant differences between low and high tumor grades, like methionine adenosyl transferase II, beta. Conclusions: The present study identified some genes, that can be used as molecular biomarkers or target genes in Egyptian bladder cancer patients.
- 29 April 2015
- Published by Asian Pacific Organization for Cancer Prevention in Asian Pacific Journal of Cancer Prevention
- Vol. 16 (8) , 3543-3549
Open AccessDifferentially Expressed Genes in Metastatic Advanced Egyptian Bladder Cancer
Background: Bladder cancer is one of the most common cancers worldwide. Gene expression profiling using microarray technologies improves the understanding of cancer biology. The aim of this study was to determine the gene expression profile in Egyptian bladder cancer patients. Materials and Methods: Samples from 29 human bladder cancers and adjacent non-neoplastic tissues were analyzed by cDNA microarray, with hierarchical clustering and multidimensional analysis. Results: Five hundred and sixteen genes were differentially expressed of which SOS1, HDAC2, PLXNC1, GTSE1, ULK2, IRS2, ABCA12, TOP3A, HES1, and SRP68 genes were involved in 33 different pathways. The most frequently detected genes were: SOS1 in 20 different pathways; HDAC2 in 5 different pathways; IRS2 in 3 different pathways. There were 388 down-regulated genes. PLCB2 was involved in 11 different pathways, MDM2 in 9 pathways, FZD4 in 5 pathways, p15 and FGF12 in 4 pathways, POLE2 in 3 pathways, and MCM4 and POLR2E in 2 pathways. Thirty genes showed significant differences between transitional cell cancer (TCC) and squamous cell cancer (SCC) samples. Unsupervised cluster analysis of DNA microarray data revealed a clear distinction between low and high grade tumors. In addition 26 genes showed significant differences between low and high tumor stages, including fragile histidine triad, Ras and sialyltransferase 8 (alpha) and 16 showed significant differences between low and high tumor grades, like methionine adenosyl transferase II, beta. Conclusions: The present study identified some genes, that can be used as molecular biomarkers or target genes in Egyptian bladder cancer patients.